Match!

Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis.

Published on Oct 1, 2019in Journal of The American Academy of Dermatology7.102
· DOI :10.1016/j.jaad.2019.06.018
Alexander Egeberg19
Estimated H-index: 19
(UCPH: University of Copenhagen),
Jacob P. Thyssen46
Estimated H-index: 46
(UCPH: University of Copenhagen)
Abstract
Abstract Background Factors that are associated with patient-reported importance of obtaining complete or almost complete clearance of psoriasis and atopic dermatitis (AD) are unknown. Objectives To investigate the importance, and associated factors, of obtaining complete or almost complete clearance of psoriasis or AD. Methods A cross-sectional study of 4,016 and 3,842 adults with psoriasis and AD. Results AD patients reported significantly greater importance of almost complete or complete skin clearance compared with psoriasis. For both patient groups, almost complete was more important that complete skin clearance. Increasing disease severity as well as itch and skin pain were significantly associated with perceived importance of skin clearance in both diseases. AD and psoriasis located on the face or neck, as well as psoriasis located on the palms, soles or genitals were significantly associated with patient-perceived importance of almost complete skin clearance. Only 7% and 27% of patients with severe AD and psoriasis, respectively, were currently on a systemic therapy. Limitations Specific reasons for infrequent use of systemic treatments was not examined. Conclusion Patients with psoriasis or AD express a strong request for almost complete or complete skin clearance. Patient education and effective therapies should be utilized to reduce disease severity.
  • References (14)
  • Citations (0)
📖 Papers frequently viewed together
2014
3 Authors (Maeve Lynch, ..., Richard B. Warren)
3 Citations
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References14
Newest
#1Andrew BlauveltH-Index: 54
#2D. RosmarinH-Index: 1
Last. Marius ArdeleanuH-Index: 11
view all 14 authors...
2 CitationsSource
#1Jonathan I. Silverberg (NU: Northwestern University)H-Index: 40
#2Eric L. Simpson (OHSU: Oregon Health & Science University)H-Index: 42
Last. Bolanle Akinlade (Regeneron)H-Index: 7
view all 17 authors...
2 CitationsSource
#1Alexander Egeberg (Gentofte Hospital)H-Index: 19
#2Y.M.F. Andersen (Gentofte Hospital)H-Index: 7
Last. Jacob P. Thyssen (Gentofte Hospital)H-Index: 46
view all 3 authors...
Background Wide-ranging psoriasis prevalence estimates have been reported, possibly due to methodological differences. Objectives To assess the prevalence of psoriasis in Denmark and to validate the use of questionnaire-based data to identify patients with psoriasis. Methods We used data from the Danish Skin Cohort, a prospective cohort comprising general population adults, as well as patients with dermatologist-verified psoriasis and atopic dermatitis, respectively. The general population cohor...
3 CitationsSource
#1Kenneth B. Gordon (MCW: Medical College of Wisconsin)H-Index: 57
#2Bruce E. Strober (University of Connecticut Health Center)H-Index: 42
Last. Hervé Bachelez (Paris Diderot University)H-Index: 44
view all 17 authors...
Summary Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We aimed to assess the efficacy and safety of risankizumab compared with placebo or ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Methods UltIMMa-1 and UltIMMa-2 were replicate phase 3, randomised, double-blind, placebo-controlled and active comparator-controlled trials done at 139...
48 CitationsSource
#1Yukari Okubo (TMU: Tokyo Medical University)H-Index: 13
#2Daisuke Tsuruta (OCU: Osaka City University)H-Index: 23
Last. Mamitaro Ohtsuki (Jichi Medical University)H-Index: 23
view all 7 authors...
Abstract Appropriate goal-oriented treatment strategies are important for optimal treatment outcomes and may prevent under-treatment. As treatment goals vary by patient, a study to examine treatment goals is more meaningful when patients and their physicians are paired. There has not been any study that examines alignment between paired psoriasis patients and physicians in real-world clinical practice using skin clearance as a treatment goal indicator. To evaluate treatment goal alignment betwee...
5 CitationsSource
#1Alexander Egeberg (UCPH: University of Copenhagen)H-Index: 19
#2M.B. Ottosen (UCPH: University of Copenhagen)H-Index: 1
Last. L. Skov (UCPH: University of Copenhagen)H-Index: 15
view all 8 authors...
Background Real-life data on newer biologic and biosimilar agents for moderate-to-severe psoriasis are lacking. Objectives To examine safety, efficacy, and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). Methods The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologi...
52 CitationsSource
#1Lluís PuigH-Index: 38
#2Matthias Augustin (UHH: University of Hamburg)H-Index: 47
Last. Mark Lebwohl (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 82
view all 13 authors...
Background Secukinumab has demonstrated greater sustained skin clearance than ustekinumab through week 52, greater improvement in symptoms and health-related quality of life, and comparable safety profile. Objective To assess the impact of secukinumab versus that of ustekinumab on complete relief from psoriasis-related symptoms, time to response in terms of health-related quality of life, and cumulative benefit among patients with moderate-to-severe plaque psoriasis. Methods Psoriasis-related pa...
8 CitationsSource
#1Bruce E. Strober (UConn: University of Connecticut)H-Index: 42
#2Kim PappH-Index: 70
Last. Paul Klekotka (Amgen)H-Index: 16
view all 15 authors...
Background New psoriasis therapies have increased the ability to achieve skin clearance. However, insufficient evidence exists on the impact of total skin clearance from the patient perspective. Objective We sought to determine if complete skin clearance is clinically meaningful compared with treatment responses without clearance. Methods Pooled data from 3 phase-III trials were used to compare results for patients with complete skin clearance (Psoriasis Area and Severity Index [PASI] 100 or sta...
29 CitationsSource
#1Steven R. Feldman (Wake Forest University)H-Index: 71
#2Donald M. BushnellH-Index: 25
Last. Hema N. Viswanathan (Amgen)H-Index: 14
view all 10 authors...
AbstractIntroduction: In psoriasis clinical trials, treatment success is often defined as achieving a static Physician Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). Patients with clear versus almost clear skin may experience psoriasis differently. This study assessed whether aggregating these patients underestimates subjective improvements associated with total skin clearance. Methods: Patients with plaque psoriasis with stable sPGA 0 or 1 currently treated with adalimumab, et...
6 CitationsSource
Background The Danish National Patient Registry (DNPR) is one of the world’s oldest nationwide hospital registries and is used extensively for research. Many studies have validated algorithms for identifying health events in the DNPR, but the reports are fragmented and no overview exists.
702 CitationsSource
Cited By0
Newest
#1Thomas H. Andreasen (UCPH: University of Copenhagen)
#2Maria O. Christensen (UCPH: University of Copenhagen)H-Index: 1
Last. Jacob P. Thyssen (UCPH: University of Copenhagen)H-Index: 46
view all 5 authors...
A growing number of clinical trials of biological and systemic therapies have been conducted within adult atopic dermatitis (AD). No study has yet examined and meta-analysed the pooled placebo response in AD. We performed a systematic review and meta-analysis to examine the placebo response in clinical trials evaluating the effect of systemic and biological therapies in adult AD and compared it to results from clinical trials in psoriasis. Two screeners independently searched the databases Clini...
Source
#1Alexander Egeberg (UCPH: University of Copenhagen)H-Index: 19
#2Griffiths Cem (University of Manchester)H-Index: 99
Last. Jacob P. Thyssen (UCPH: University of Copenhagen)H-Index: 46
view all 5 authors...
1 CitationsSource
#1L. E. M. de Wijs (EUR: Erasmus University Rotterdam)H-Index: 1
#2N.T. Nguyen (EUR: Erasmus University Rotterdam)H-Index: 1
Last. DirkJan Hijnen (EUR: Erasmus University Rotterdam)H-Index: 22
view all 6 authors...
textabstractDupilumab is the first biologic registered for the treatment of atopic dermatitis (AD). We report on seven patients with AD presenting with a paradoxical head and neck erythema that appeared 10–39 weeks after the start of dupilumab treatment. The patients presented with a relatively sharply demarcated, patchy erythema in the head and neck area that showed no or less scaling compared with their usual eczema. Only one patient experienced symptoms of itch and burning, although this was ...
3 CitationsSource